Binding molecules binding PD-L1 and LAG-3
US11214620B2 · kind B2 · utility
10Cited by
8References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2017 |
| Grant date | Jan 4, 2022 |
| Priority date | — |
| Expiry date | Aug 28, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2318/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.